Global Eosinophilic Disease Market Growth 2026-2032
The global Eosinophilic Disease market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Eosinophils are the variety of white infection, allergy blood cells and one of the major immune system components helps in combating various and inflammatory diseases. Eosinophils develops and mature in the bone marrow and represent upto 6% of bone marrow. If the threshold of 1500?cells/?l crosses called as eosinophil-driven diseases, which causes severe inflammatory diseases and organ damage.
United States market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Eosinophilic Disease players cover Takeda Pharmaceutical Company Limited, Ellodi Pharmaceuticals, Bristol-Myers Squibb Company, AstraZeneca, GSK plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Eosinophilic Disease Industry Forecast? looks at past sales and reviews total world Eosinophilic Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Eosinophilic Disease sales for 2026 through 2032. With Eosinophilic Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eosinophilic Disease industry.
This Insight Report provides a comprehensive analysis of the global Eosinophilic Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eosinophilic Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Eosinophilic Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eosinophilic Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eosinophilic Disease.
This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Eosinophils are the variety of white infection, allergy blood cells and one of the major immune system components helps in combating various and inflammatory diseases. Eosinophils develops and mature in the bone marrow and represent upto 6% of bone marrow. If the threshold of 1500?cells/?l crosses called as eosinophil-driven diseases, which causes severe inflammatory diseases and organ damage.
United States market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Eosinophilic Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Eosinophilic Disease players cover Takeda Pharmaceutical Company Limited, Ellodi Pharmaceuticals, Bristol-Myers Squibb Company, AstraZeneca, GSK plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Eosinophilic Disease Industry Forecast? looks at past sales and reviews total world Eosinophilic Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Eosinophilic Disease sales for 2026 through 2032. With Eosinophilic Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eosinophilic Disease industry.
This Insight Report provides a comprehensive analysis of the global Eosinophilic Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eosinophilic Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Eosinophilic Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eosinophilic Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eosinophilic Disease.
This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Corticosteroids
- Monoclonal Antibodies
- Anti-cytokine Drug
- Cytotoxic Drug
- Eosinophilic Esophagitis
- Eosinophilic Granulomatosis with Polyangiitis
- Hyper-eosinophilic Syndrome
- Nasal Polyposis
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Takeda Pharmaceutical Company Limited
- Ellodi Pharmaceuticals
- Bristol-Myers Squibb Company
- AstraZeneca
- GSK plc
- Regeneron Pharmaceuticals Inc
- Allakos Inc
- Arena Pharmaceuticals Ltd
- Revolo Biotherapeutics
- DBV Technologies
- Cipla Inc
- Sun Pharmaceutical Industries Ltd
- Sanofi
- What is the 10-year outlook for the global Eosinophilic Disease market?
- What factors are driving Eosinophilic Disease market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Eosinophilic Disease market opportunities vary by end market size?
- How does Eosinophilic Disease break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Eosinophilic Disease Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Eosinophilic Disease by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Eosinophilic Disease by Country/Region, 2021, 2025 & 2032
2.2 Eosinophilic Disease Segment by Type
2.2.1 Corticosteroids
2.2.2 Monoclonal Antibodies
2.2.3 Anti-cytokine Drug
2.2.4 Cytotoxic Drug
2.2.5 Eosinophilic Disease Sales by Type
2.2.5.1 Global Eosinophilic Disease Sales Market Share by Type (2021-2026)
2.2.5.2 Global Eosinophilic Disease Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Eosinophilic Disease Sale Price by Type (2021-2026)
2.3 Eosinophilic Disease Segment by Application
2.3.1 Eosinophilic Esophagitis
2.3.2 Eosinophilic Granulomatosis with Polyangiitis
2.3.3 Hyper-eosinophilic Syndrome
2.3.4 Nasal Polyposis
2.3.5 Other
2.3.6 Eosinophilic Disease Sales by Application
2.3.6.1 Global Eosinophilic Disease Sale Market Share by Application (2021-2026)
2.3.6.2 Global Eosinophilic Disease Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Eosinophilic Disease Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Eosinophilic Disease Breakdown Data by Company
3.1.1 Global Eosinophilic Disease Annual Sales by Company (2021-2026)
3.1.2 Global Eosinophilic Disease Sales Market Share by Company (2021-2026)
3.2 Global Eosinophilic Disease Annual Revenue by Company (2021-2026)
3.2.1 Global Eosinophilic Disease Revenue by Company (2021-2026)
3.2.2 Global Eosinophilic Disease Revenue Market Share by Company (2021-2026)
3.3 Global Eosinophilic Disease Sale Price by Company
3.4 Key Manufacturers Eosinophilic Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Eosinophilic Disease Product Location Distribution
3.4.2 Players Eosinophilic Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR EOSINOPHILIC DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Eosinophilic Disease Market Size by Geographic Region (2021-2026)
4.1.1 Global Eosinophilic Disease Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Eosinophilic Disease Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Eosinophilic Disease Market Size by Country/Region (2021-2026)
4.2.1 Global Eosinophilic Disease Annual Sales by Country/Region (2021-2026)
4.2.2 Global Eosinophilic Disease Annual Revenue by Country/Region (2021-2026)
4.3 Americas Eosinophilic Disease Sales Growth
4.4 APAC Eosinophilic Disease Sales Growth
4.5 Europe Eosinophilic Disease Sales Growth
4.6 Middle East & Africa Eosinophilic Disease Sales Growth
5 AMERICAS
5.1 Americas Eosinophilic Disease Sales by Country
5.1.1 Americas Eosinophilic Disease Sales by Country (2021-2026)
5.1.2 Americas Eosinophilic Disease Revenue by Country (2021-2026)
5.2 Americas Eosinophilic Disease Sales by Type (2021-2026)
5.3 Americas Eosinophilic Disease Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Eosinophilic Disease Sales by Region
6.1.1 APAC Eosinophilic Disease Sales by Region (2021-2026)
6.1.2 APAC Eosinophilic Disease Revenue by Region (2021-2026)
6.2 APAC Eosinophilic Disease Sales by Type (2021-2026)
6.3 APAC Eosinophilic Disease Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Eosinophilic Disease by Country
7.1.1 Europe Eosinophilic Disease Sales by Country (2021-2026)
7.1.2 Europe Eosinophilic Disease Revenue by Country (2021-2026)
7.2 Europe Eosinophilic Disease Sales by Type (2021-2026)
7.3 Europe Eosinophilic Disease Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Eosinophilic Disease by Country
8.1.1 Middle East & Africa Eosinophilic Disease Sales by Country (2021-2026)
8.1.2 Middle East & Africa Eosinophilic Disease Revenue by Country (2021-2026)
8.2 Middle East & Africa Eosinophilic Disease Sales by Type (2021-2026)
8.3 Middle East & Africa Eosinophilic Disease Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Eosinophilic Disease
10.3 Manufacturing Process Analysis of Eosinophilic Disease
10.4 Industry Chain Structure of Eosinophilic Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Eosinophilic Disease Distributors
11.3 Eosinophilic Disease Customer
12 WORLD FORECAST REVIEW FOR EOSINOPHILIC DISEASE BY GEOGRAPHIC REGION
12.1 Global Eosinophilic Disease Market Size Forecast by Region
12.1.1 Global Eosinophilic Disease Forecast by Region (2027-2032)
12.1.2 Global Eosinophilic Disease Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Eosinophilic Disease Forecast by Type (2027-2032)
12.7 Global Eosinophilic Disease Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Takeda Pharmaceutical Company Limited Company Information
13.1.2 Takeda Pharmaceutical Company Limited Eosinophilic Disease Product Portfolios and Specifications
13.1.3 Takeda Pharmaceutical Company Limited Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.1.5 Takeda Pharmaceutical Company Limited Latest Developments
13.2 Ellodi Pharmaceuticals
13.2.1 Ellodi Pharmaceuticals Company Information
13.2.2 Ellodi Pharmaceuticals Eosinophilic Disease Product Portfolios and Specifications
13.2.3 Ellodi Pharmaceuticals Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ellodi Pharmaceuticals Main Business Overview
13.2.5 Ellodi Pharmaceuticals Latest Developments
13.3 Bristol-Myers Squibb Company
13.3.1 Bristol-Myers Squibb Company Company Information
13.3.2 Bristol-Myers Squibb Company Eosinophilic Disease Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Company Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bristol-Myers Squibb Company Main Business Overview
13.3.5 Bristol-Myers Squibb Company Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Eosinophilic Disease Product Portfolios and Specifications
13.4.3 AstraZeneca Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 GSK plc
13.5.1 GSK plc Company Information
13.5.2 GSK plc Eosinophilic Disease Product Portfolios and Specifications
13.5.3 GSK plc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 GSK plc Main Business Overview
13.5.5 GSK plc Latest Developments
13.6 Regeneron Pharmaceuticals Inc
13.6.1 Regeneron Pharmaceuticals Inc Company Information
13.6.2 Regeneron Pharmaceuticals Inc Eosinophilic Disease Product Portfolios and Specifications
13.6.3 Regeneron Pharmaceuticals Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.6.5 Regeneron Pharmaceuticals Inc Latest Developments
13.7 Allakos Inc
13.7.1 Allakos Inc Company Information
13.7.2 Allakos Inc Eosinophilic Disease Product Portfolios and Specifications
13.7.3 Allakos Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Allakos Inc Main Business Overview
13.7.5 Allakos Inc Latest Developments
13.8 Arena Pharmaceuticals Ltd
13.8.1 Arena Pharmaceuticals Ltd Company Information
13.8.2 Arena Pharmaceuticals Ltd Eosinophilic Disease Product Portfolios and Specifications
13.8.3 Arena Pharmaceuticals Ltd Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Arena Pharmaceuticals Ltd Main Business Overview
13.8.5 Arena Pharmaceuticals Ltd Latest Developments
13.9 Revolo Biotherapeutics
13.9.1 Revolo Biotherapeutics Company Information
13.9.2 Revolo Biotherapeutics Eosinophilic Disease Product Portfolios and Specifications
13.9.3 Revolo Biotherapeutics Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Revolo Biotherapeutics Main Business Overview
13.9.5 Revolo Biotherapeutics Latest Developments
13.10 DBV Technologies
13.10.1 DBV Technologies Company Information
13.10.2 DBV Technologies Eosinophilic Disease Product Portfolios and Specifications
13.10.3 DBV Technologies Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 DBV Technologies Main Business Overview
13.10.5 DBV Technologies Latest Developments
13.11 Cipla Inc
13.11.1 Cipla Inc Company Information
13.11.2 Cipla Inc Eosinophilic Disease Product Portfolios and Specifications
13.11.3 Cipla Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Cipla Inc Main Business Overview
13.11.5 Cipla Inc Latest Developments
13.12 Sun Pharmaceutical Industries Ltd
13.12.1 Sun Pharmaceutical Industries Ltd Company Information
13.12.2 Sun Pharmaceutical Industries Ltd Eosinophilic Disease Product Portfolios and Specifications
13.12.3 Sun Pharmaceutical Industries Ltd Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.12.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.13 Sanofi
13.13.1 Sanofi Company Information
13.13.2 Sanofi Eosinophilic Disease Product Portfolios and Specifications
13.13.3 Sanofi Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sanofi Main Business Overview
13.13.5 Sanofi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Eosinophilic Disease Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Eosinophilic Disease by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Eosinophilic Disease by Country/Region, 2021, 2025 & 2032
2.2 Eosinophilic Disease Segment by Type
2.2.1 Corticosteroids
2.2.2 Monoclonal Antibodies
2.2.3 Anti-cytokine Drug
2.2.4 Cytotoxic Drug
2.2.5 Eosinophilic Disease Sales by Type
2.2.5.1 Global Eosinophilic Disease Sales Market Share by Type (2021-2026)
2.2.5.2 Global Eosinophilic Disease Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Eosinophilic Disease Sale Price by Type (2021-2026)
2.3 Eosinophilic Disease Segment by Application
2.3.1 Eosinophilic Esophagitis
2.3.2 Eosinophilic Granulomatosis with Polyangiitis
2.3.3 Hyper-eosinophilic Syndrome
2.3.4 Nasal Polyposis
2.3.5 Other
2.3.6 Eosinophilic Disease Sales by Application
2.3.6.1 Global Eosinophilic Disease Sale Market Share by Application (2021-2026)
2.3.6.2 Global Eosinophilic Disease Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Eosinophilic Disease Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Eosinophilic Disease Breakdown Data by Company
3.1.1 Global Eosinophilic Disease Annual Sales by Company (2021-2026)
3.1.2 Global Eosinophilic Disease Sales Market Share by Company (2021-2026)
3.2 Global Eosinophilic Disease Annual Revenue by Company (2021-2026)
3.2.1 Global Eosinophilic Disease Revenue by Company (2021-2026)
3.2.2 Global Eosinophilic Disease Revenue Market Share by Company (2021-2026)
3.3 Global Eosinophilic Disease Sale Price by Company
3.4 Key Manufacturers Eosinophilic Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Eosinophilic Disease Product Location Distribution
3.4.2 Players Eosinophilic Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR EOSINOPHILIC DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Eosinophilic Disease Market Size by Geographic Region (2021-2026)
4.1.1 Global Eosinophilic Disease Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Eosinophilic Disease Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Eosinophilic Disease Market Size by Country/Region (2021-2026)
4.2.1 Global Eosinophilic Disease Annual Sales by Country/Region (2021-2026)
4.2.2 Global Eosinophilic Disease Annual Revenue by Country/Region (2021-2026)
4.3 Americas Eosinophilic Disease Sales Growth
4.4 APAC Eosinophilic Disease Sales Growth
4.5 Europe Eosinophilic Disease Sales Growth
4.6 Middle East & Africa Eosinophilic Disease Sales Growth
5 AMERICAS
5.1 Americas Eosinophilic Disease Sales by Country
5.1.1 Americas Eosinophilic Disease Sales by Country (2021-2026)
5.1.2 Americas Eosinophilic Disease Revenue by Country (2021-2026)
5.2 Americas Eosinophilic Disease Sales by Type (2021-2026)
5.3 Americas Eosinophilic Disease Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Eosinophilic Disease Sales by Region
6.1.1 APAC Eosinophilic Disease Sales by Region (2021-2026)
6.1.2 APAC Eosinophilic Disease Revenue by Region (2021-2026)
6.2 APAC Eosinophilic Disease Sales by Type (2021-2026)
6.3 APAC Eosinophilic Disease Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Eosinophilic Disease by Country
7.1.1 Europe Eosinophilic Disease Sales by Country (2021-2026)
7.1.2 Europe Eosinophilic Disease Revenue by Country (2021-2026)
7.2 Europe Eosinophilic Disease Sales by Type (2021-2026)
7.3 Europe Eosinophilic Disease Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Eosinophilic Disease by Country
8.1.1 Middle East & Africa Eosinophilic Disease Sales by Country (2021-2026)
8.1.2 Middle East & Africa Eosinophilic Disease Revenue by Country (2021-2026)
8.2 Middle East & Africa Eosinophilic Disease Sales by Type (2021-2026)
8.3 Middle East & Africa Eosinophilic Disease Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Eosinophilic Disease
10.3 Manufacturing Process Analysis of Eosinophilic Disease
10.4 Industry Chain Structure of Eosinophilic Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Eosinophilic Disease Distributors
11.3 Eosinophilic Disease Customer
12 WORLD FORECAST REVIEW FOR EOSINOPHILIC DISEASE BY GEOGRAPHIC REGION
12.1 Global Eosinophilic Disease Market Size Forecast by Region
12.1.1 Global Eosinophilic Disease Forecast by Region (2027-2032)
12.1.2 Global Eosinophilic Disease Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Eosinophilic Disease Forecast by Type (2027-2032)
12.7 Global Eosinophilic Disease Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Takeda Pharmaceutical Company Limited Company Information
13.1.2 Takeda Pharmaceutical Company Limited Eosinophilic Disease Product Portfolios and Specifications
13.1.3 Takeda Pharmaceutical Company Limited Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.1.5 Takeda Pharmaceutical Company Limited Latest Developments
13.2 Ellodi Pharmaceuticals
13.2.1 Ellodi Pharmaceuticals Company Information
13.2.2 Ellodi Pharmaceuticals Eosinophilic Disease Product Portfolios and Specifications
13.2.3 Ellodi Pharmaceuticals Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ellodi Pharmaceuticals Main Business Overview
13.2.5 Ellodi Pharmaceuticals Latest Developments
13.3 Bristol-Myers Squibb Company
13.3.1 Bristol-Myers Squibb Company Company Information
13.3.2 Bristol-Myers Squibb Company Eosinophilic Disease Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Company Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bristol-Myers Squibb Company Main Business Overview
13.3.5 Bristol-Myers Squibb Company Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Eosinophilic Disease Product Portfolios and Specifications
13.4.3 AstraZeneca Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 GSK plc
13.5.1 GSK plc Company Information
13.5.2 GSK plc Eosinophilic Disease Product Portfolios and Specifications
13.5.3 GSK plc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 GSK plc Main Business Overview
13.5.5 GSK plc Latest Developments
13.6 Regeneron Pharmaceuticals Inc
13.6.1 Regeneron Pharmaceuticals Inc Company Information
13.6.2 Regeneron Pharmaceuticals Inc Eosinophilic Disease Product Portfolios and Specifications
13.6.3 Regeneron Pharmaceuticals Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.6.5 Regeneron Pharmaceuticals Inc Latest Developments
13.7 Allakos Inc
13.7.1 Allakos Inc Company Information
13.7.2 Allakos Inc Eosinophilic Disease Product Portfolios and Specifications
13.7.3 Allakos Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Allakos Inc Main Business Overview
13.7.5 Allakos Inc Latest Developments
13.8 Arena Pharmaceuticals Ltd
13.8.1 Arena Pharmaceuticals Ltd Company Information
13.8.2 Arena Pharmaceuticals Ltd Eosinophilic Disease Product Portfolios and Specifications
13.8.3 Arena Pharmaceuticals Ltd Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Arena Pharmaceuticals Ltd Main Business Overview
13.8.5 Arena Pharmaceuticals Ltd Latest Developments
13.9 Revolo Biotherapeutics
13.9.1 Revolo Biotherapeutics Company Information
13.9.2 Revolo Biotherapeutics Eosinophilic Disease Product Portfolios and Specifications
13.9.3 Revolo Biotherapeutics Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Revolo Biotherapeutics Main Business Overview
13.9.5 Revolo Biotherapeutics Latest Developments
13.10 DBV Technologies
13.10.1 DBV Technologies Company Information
13.10.2 DBV Technologies Eosinophilic Disease Product Portfolios and Specifications
13.10.3 DBV Technologies Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 DBV Technologies Main Business Overview
13.10.5 DBV Technologies Latest Developments
13.11 Cipla Inc
13.11.1 Cipla Inc Company Information
13.11.2 Cipla Inc Eosinophilic Disease Product Portfolios and Specifications
13.11.3 Cipla Inc Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Cipla Inc Main Business Overview
13.11.5 Cipla Inc Latest Developments
13.12 Sun Pharmaceutical Industries Ltd
13.12.1 Sun Pharmaceutical Industries Ltd Company Information
13.12.2 Sun Pharmaceutical Industries Ltd Eosinophilic Disease Product Portfolios and Specifications
13.12.3 Sun Pharmaceutical Industries Ltd Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.12.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.13 Sanofi
13.13.1 Sanofi Company Information
13.13.2 Sanofi Eosinophilic Disease Product Portfolios and Specifications
13.13.3 Sanofi Eosinophilic Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sanofi Main Business Overview
13.13.5 Sanofi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Eosinophilic Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Eosinophilic Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Corticosteroids
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of Anti-cytokine Drug
Table 6. Major Players of Cytotoxic Drug
Table 7. Global Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 8. Global Eosinophilic Disease Sales Market Share by Type (2021-2026)
Table 9. Global Eosinophilic Disease Revenue by Type (2021-2026) & ($ million)
Table 10. Global Eosinophilic Disease Revenue Market Share by Type (2021-2026)
Table 11. Global Eosinophilic Disease Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Eosinophilic Disease Sale by Application (2021-2026) & (K Units)
Table 13. Global Eosinophilic Disease Sale Market Share by Application (2021-2026)
Table 14. Global Eosinophilic Disease Revenue by Application (2021-2026) & ($ million)
Table 15. Global Eosinophilic Disease Revenue Market Share by Application (2021-2026)
Table 16. Global Eosinophilic Disease Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Eosinophilic Disease Sales by Company (2021-2026) & (K Units)
Table 18. Global Eosinophilic Disease Sales Market Share by Company (2021-2026)
Table 19. Global Eosinophilic Disease Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Eosinophilic Disease Revenue Market Share by Company (2021-2026)
Table 21. Global Eosinophilic Disease Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Eosinophilic Disease Producing Area Distribution and Sales Area
Table 23. Players Eosinophilic Disease Products Offered
Table 24. Eosinophilic Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Eosinophilic Disease Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Eosinophilic Disease Sales Market Share Geographic Region (2021-2026)
Table 29. Global Eosinophilic Disease Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Eosinophilic Disease Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Eosinophilic Disease Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Eosinophilic Disease Sales Market Share by Country/Region (2021-2026)
Table 33. Global Eosinophilic Disease Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Eosinophilic Disease Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 36. Americas Eosinophilic Disease Sales Market Share by Country (2021-2026)
Table 37. Americas Eosinophilic Disease Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 39. Americas Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 40. APAC Eosinophilic Disease Sales by Region (2021-2026) & (K Units)
Table 41. APAC Eosinophilic Disease Sales Market Share by Region (2021-2026)
Table 42. APAC Eosinophilic Disease Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 44. APAC Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 45. Europe Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 46. Europe Eosinophilic Disease Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 48. Europe Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Eosinophilic Disease
Table 54. Key Market Challenges & Risks of Eosinophilic Disease
Table 55. Key Industry Trends of Eosinophilic Disease
Table 56. Eosinophilic Disease Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Eosinophilic Disease Distributors List
Table 59. Eosinophilic Disease Customer List
Table 60. Global Eosinophilic Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Eosinophilic Disease Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Eosinophilic Disease Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Eosinophilic Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Eosinophilic Disease Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Eosinophilic Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Eosinophilic Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Eosinophilic Disease Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Eosinophilic Disease Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Eosinophilic Disease Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Eosinophilic Disease Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Takeda Pharmaceutical Company Limited Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 75. Takeda Pharmaceutical Company Limited Eosinophilic Disease Product Portfolios and Specifications
Table 76. Takeda Pharmaceutical Company Limited Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Takeda Pharmaceutical Company Limited Main Business
Table 78. Takeda Pharmaceutical Company Limited Latest Developments
Table 79. Ellodi Pharmaceuticals Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 80. Ellodi Pharmaceuticals Eosinophilic Disease Product Portfolios and Specifications
Table 81. Ellodi Pharmaceuticals Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Ellodi Pharmaceuticals Main Business
Table 83. Ellodi Pharmaceuticals Latest Developments
Table 84. Bristol-Myers Squibb Company Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 85. Bristol-Myers Squibb Company Eosinophilic Disease Product Portfolios and Specifications
Table 86. Bristol-Myers Squibb Company Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Bristol-Myers Squibb Company Main Business
Table 88. Bristol-Myers Squibb Company Latest Developments
Table 89. AstraZeneca Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 90. AstraZeneca Eosinophilic Disease Product Portfolios and Specifications
Table 91. AstraZeneca Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. AstraZeneca Main Business
Table 93. AstraZeneca Latest Developments
Table 94. GSK plc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 95. GSK plc Eosinophilic Disease Product Portfolios and Specifications
Table 96. GSK plc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. GSK plc Main Business
Table 98. GSK plc Latest Developments
Table 99. Regeneron Pharmaceuticals Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 100. Regeneron Pharmaceuticals Inc Eosinophilic Disease Product Portfolios and Specifications
Table 101. Regeneron Pharmaceuticals Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Regeneron Pharmaceuticals Inc Main Business
Table 103. Regeneron Pharmaceuticals Inc Latest Developments
Table 104. Allakos Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 105. Allakos Inc Eosinophilic Disease Product Portfolios and Specifications
Table 106. Allakos Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Allakos Inc Main Business
Table 108. Allakos Inc Latest Developments
Table 109. Arena Pharmaceuticals Ltd Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 110. Arena Pharmaceuticals Ltd Eosinophilic Disease Product Portfolios and Specifications
Table 111. Arena Pharmaceuticals Ltd Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Arena Pharmaceuticals Ltd Main Business
Table 113. Arena Pharmaceuticals Ltd Latest Developments
Table 114. Revolo Biotherapeutics Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 115. Revolo Biotherapeutics Eosinophilic Disease Product Portfolios and Specifications
Table 116. Revolo Biotherapeutics Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Revolo Biotherapeutics Main Business
Table 118. Revolo Biotherapeutics Latest Developments
Table 119. DBV Technologies Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 120. DBV Technologies Eosinophilic Disease Product Portfolios and Specifications
Table 121. DBV Technologies Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. DBV Technologies Main Business
Table 123. DBV Technologies Latest Developments
Table 124. Cipla Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 125. Cipla Inc Eosinophilic Disease Product Portfolios and Specifications
Table 126. Cipla Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Cipla Inc Main Business
Table 128. Cipla Inc Latest Developments
Table 129. Sun Pharmaceutical Industries Ltd Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 130. Sun Pharmaceutical Industries Ltd Eosinophilic Disease Product Portfolios and Specifications
Table 131. Sun Pharmaceutical Industries Ltd Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Sun Pharmaceutical Industries Ltd Main Business
Table 133. Sun Pharmaceutical Industries Ltd Latest Developments
Table 134. Sanofi Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 135. Sanofi Eosinophilic Disease Product Portfolios and Specifications
Table 136. Sanofi Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Sanofi Main Business
Table 138. Sanofi Latest Developments
Table 1. Eosinophilic Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Eosinophilic Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Corticosteroids
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of Anti-cytokine Drug
Table 6. Major Players of Cytotoxic Drug
Table 7. Global Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 8. Global Eosinophilic Disease Sales Market Share by Type (2021-2026)
Table 9. Global Eosinophilic Disease Revenue by Type (2021-2026) & ($ million)
Table 10. Global Eosinophilic Disease Revenue Market Share by Type (2021-2026)
Table 11. Global Eosinophilic Disease Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Eosinophilic Disease Sale by Application (2021-2026) & (K Units)
Table 13. Global Eosinophilic Disease Sale Market Share by Application (2021-2026)
Table 14. Global Eosinophilic Disease Revenue by Application (2021-2026) & ($ million)
Table 15. Global Eosinophilic Disease Revenue Market Share by Application (2021-2026)
Table 16. Global Eosinophilic Disease Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Eosinophilic Disease Sales by Company (2021-2026) & (K Units)
Table 18. Global Eosinophilic Disease Sales Market Share by Company (2021-2026)
Table 19. Global Eosinophilic Disease Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Eosinophilic Disease Revenue Market Share by Company (2021-2026)
Table 21. Global Eosinophilic Disease Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Eosinophilic Disease Producing Area Distribution and Sales Area
Table 23. Players Eosinophilic Disease Products Offered
Table 24. Eosinophilic Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Eosinophilic Disease Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Eosinophilic Disease Sales Market Share Geographic Region (2021-2026)
Table 29. Global Eosinophilic Disease Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Eosinophilic Disease Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Eosinophilic Disease Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Eosinophilic Disease Sales Market Share by Country/Region (2021-2026)
Table 33. Global Eosinophilic Disease Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Eosinophilic Disease Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 36. Americas Eosinophilic Disease Sales Market Share by Country (2021-2026)
Table 37. Americas Eosinophilic Disease Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 39. Americas Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 40. APAC Eosinophilic Disease Sales by Region (2021-2026) & (K Units)
Table 41. APAC Eosinophilic Disease Sales Market Share by Region (2021-2026)
Table 42. APAC Eosinophilic Disease Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 44. APAC Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 45. Europe Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 46. Europe Eosinophilic Disease Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 48. Europe Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Eosinophilic Disease Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Eosinophilic Disease Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Eosinophilic Disease Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Eosinophilic Disease
Table 54. Key Market Challenges & Risks of Eosinophilic Disease
Table 55. Key Industry Trends of Eosinophilic Disease
Table 56. Eosinophilic Disease Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Eosinophilic Disease Distributors List
Table 59. Eosinophilic Disease Customer List
Table 60. Global Eosinophilic Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Eosinophilic Disease Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Eosinophilic Disease Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Eosinophilic Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Eosinophilic Disease Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Eosinophilic Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Eosinophilic Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Eosinophilic Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Eosinophilic Disease Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Eosinophilic Disease Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Eosinophilic Disease Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Eosinophilic Disease Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Takeda Pharmaceutical Company Limited Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 75. Takeda Pharmaceutical Company Limited Eosinophilic Disease Product Portfolios and Specifications
Table 76. Takeda Pharmaceutical Company Limited Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Takeda Pharmaceutical Company Limited Main Business
Table 78. Takeda Pharmaceutical Company Limited Latest Developments
Table 79. Ellodi Pharmaceuticals Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 80. Ellodi Pharmaceuticals Eosinophilic Disease Product Portfolios and Specifications
Table 81. Ellodi Pharmaceuticals Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Ellodi Pharmaceuticals Main Business
Table 83. Ellodi Pharmaceuticals Latest Developments
Table 84. Bristol-Myers Squibb Company Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 85. Bristol-Myers Squibb Company Eosinophilic Disease Product Portfolios and Specifications
Table 86. Bristol-Myers Squibb Company Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Bristol-Myers Squibb Company Main Business
Table 88. Bristol-Myers Squibb Company Latest Developments
Table 89. AstraZeneca Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 90. AstraZeneca Eosinophilic Disease Product Portfolios and Specifications
Table 91. AstraZeneca Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. AstraZeneca Main Business
Table 93. AstraZeneca Latest Developments
Table 94. GSK plc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 95. GSK plc Eosinophilic Disease Product Portfolios and Specifications
Table 96. GSK plc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. GSK plc Main Business
Table 98. GSK plc Latest Developments
Table 99. Regeneron Pharmaceuticals Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 100. Regeneron Pharmaceuticals Inc Eosinophilic Disease Product Portfolios and Specifications
Table 101. Regeneron Pharmaceuticals Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Regeneron Pharmaceuticals Inc Main Business
Table 103. Regeneron Pharmaceuticals Inc Latest Developments
Table 104. Allakos Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 105. Allakos Inc Eosinophilic Disease Product Portfolios and Specifications
Table 106. Allakos Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Allakos Inc Main Business
Table 108. Allakos Inc Latest Developments
Table 109. Arena Pharmaceuticals Ltd Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 110. Arena Pharmaceuticals Ltd Eosinophilic Disease Product Portfolios and Specifications
Table 111. Arena Pharmaceuticals Ltd Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Arena Pharmaceuticals Ltd Main Business
Table 113. Arena Pharmaceuticals Ltd Latest Developments
Table 114. Revolo Biotherapeutics Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 115. Revolo Biotherapeutics Eosinophilic Disease Product Portfolios and Specifications
Table 116. Revolo Biotherapeutics Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Revolo Biotherapeutics Main Business
Table 118. Revolo Biotherapeutics Latest Developments
Table 119. DBV Technologies Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 120. DBV Technologies Eosinophilic Disease Product Portfolios and Specifications
Table 121. DBV Technologies Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. DBV Technologies Main Business
Table 123. DBV Technologies Latest Developments
Table 124. Cipla Inc Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 125. Cipla Inc Eosinophilic Disease Product Portfolios and Specifications
Table 126. Cipla Inc Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Cipla Inc Main Business
Table 128. Cipla Inc Latest Developments
Table 129. Sun Pharmaceutical Industries Ltd Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 130. Sun Pharmaceutical Industries Ltd Eosinophilic Disease Product Portfolios and Specifications
Table 131. Sun Pharmaceutical Industries Ltd Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Sun Pharmaceutical Industries Ltd Main Business
Table 133. Sun Pharmaceutical Industries Ltd Latest Developments
Table 134. Sanofi Basic Information, Eosinophilic Disease Manufacturing Base, Sales Area and Its Competitors
Table 135. Sanofi Eosinophilic Disease Product Portfolios and Specifications
Table 136. Sanofi Eosinophilic Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Sanofi Main Business
Table 138. Sanofi Latest Developments
LIST OF FIGURES
Figure 1. Picture of Eosinophilic Disease
Figure 2. Eosinophilic Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Eosinophilic Disease Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Eosinophilic Disease Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Eosinophilic Disease Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Eosinophilic Disease Sales Market Share by Country/Region (2025)
Figure 10. Eosinophilic Disease Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Corticosteroids
Figure 12. Product Picture of Monoclonal Antibodies
Figure 13. Product Picture of Anti-cytokine Drug
Figure 14. Product Picture of Cytotoxic Drug
Figure 15. Global Eosinophilic Disease Sales Market Share by Type in 2026
Figure 16. Global Eosinophilic Disease Revenue Market Share by Type (2021-2026)
Figure 17. Eosinophilic Disease Consumed in Eosinophilic Esophagitis
Figure 18. Global Eosinophilic Disease Market: Eosinophilic Esophagitis (2021-2026) & (K Units)
Figure 19. Eosinophilic Disease Consumed in Eosinophilic Granulomatosis with Polyangiitis
Figure 20. Global Eosinophilic Disease Market: Eosinophilic Granulomatosis with Polyangiitis (2021-2026) & (K Units)
Figure 21. Eosinophilic Disease Consumed in Hyper-eosinophilic Syndrome
Figure 22. Global Eosinophilic Disease Market: Hyper-eosinophilic Syndrome (2021-2026) & (K Units)
Figure 23. Eosinophilic Disease Consumed in Nasal Polyposis
Figure 24. Global Eosinophilic Disease Market: Nasal Polyposis (2021-2026) & (K Units)
Figure 25. Eosinophilic Disease Consumed in Other
Figure 26. Global Eosinophilic Disease Market: Other (2021-2026) & (K Units)
Figure 27. Global Eosinophilic Disease Sale Market Share by Application (2025)
Figure 28. Global Eosinophilic Disease Revenue Market Share by Application in 2026
Figure 29. Eosinophilic Disease Sales by Company in 2026 (K Units)
Figure 30. Global Eosinophilic Disease Sales Market Share by Company in 2026
Figure 31. Eosinophilic Disease Revenue by Company in 2026 ($ millions)
Figure 32. Global Eosinophilic Disease Revenue Market Share by Company in 2026
Figure 33. Global Eosinophilic Disease Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Eosinophilic Disease Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 36. Americas Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 37. APAC Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 38. APAC Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 39. Europe Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 40. Europe Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 43. Americas Eosinophilic Disease Sales Market Share by Country in 2026
Figure 44. Americas Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Figure 45. Americas Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 46. Americas Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 47. United States Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Eosinophilic Disease Sales Market Share by Region in 2026
Figure 52. APAC Eosinophilic Disease Revenue Market Share by Region (2021-2026)
Figure 53. APAC Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 54. APAC Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 55. China Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 59. India Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Eosinophilic Disease Sales Market Share by Country in 2026
Figure 63. Europe Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Figure 64. Europe Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 65. Europe Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 66. Germany Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 67. France Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Eosinophilic Disease Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 74. Egypt Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Eosinophilic Disease in 2026
Figure 80. Manufacturing Process Analysis of Eosinophilic Disease
Figure 81. Industry Chain Structure of Eosinophilic Disease
Figure 82. Channels of Distribution
Figure 83. Global Eosinophilic Disease Sales Market Forecast by Region (2027-2032)
Figure 84. Global Eosinophilic Disease Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Eosinophilic Disease Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Eosinophilic Disease Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Eosinophilic Disease Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Eosinophilic Disease Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Eosinophilic Disease
Figure 2. Eosinophilic Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Eosinophilic Disease Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Eosinophilic Disease Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Eosinophilic Disease Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Eosinophilic Disease Sales Market Share by Country/Region (2025)
Figure 10. Eosinophilic Disease Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Corticosteroids
Figure 12. Product Picture of Monoclonal Antibodies
Figure 13. Product Picture of Anti-cytokine Drug
Figure 14. Product Picture of Cytotoxic Drug
Figure 15. Global Eosinophilic Disease Sales Market Share by Type in 2026
Figure 16. Global Eosinophilic Disease Revenue Market Share by Type (2021-2026)
Figure 17. Eosinophilic Disease Consumed in Eosinophilic Esophagitis
Figure 18. Global Eosinophilic Disease Market: Eosinophilic Esophagitis (2021-2026) & (K Units)
Figure 19. Eosinophilic Disease Consumed in Eosinophilic Granulomatosis with Polyangiitis
Figure 20. Global Eosinophilic Disease Market: Eosinophilic Granulomatosis with Polyangiitis (2021-2026) & (K Units)
Figure 21. Eosinophilic Disease Consumed in Hyper-eosinophilic Syndrome
Figure 22. Global Eosinophilic Disease Market: Hyper-eosinophilic Syndrome (2021-2026) & (K Units)
Figure 23. Eosinophilic Disease Consumed in Nasal Polyposis
Figure 24. Global Eosinophilic Disease Market: Nasal Polyposis (2021-2026) & (K Units)
Figure 25. Eosinophilic Disease Consumed in Other
Figure 26. Global Eosinophilic Disease Market: Other (2021-2026) & (K Units)
Figure 27. Global Eosinophilic Disease Sale Market Share by Application (2025)
Figure 28. Global Eosinophilic Disease Revenue Market Share by Application in 2026
Figure 29. Eosinophilic Disease Sales by Company in 2026 (K Units)
Figure 30. Global Eosinophilic Disease Sales Market Share by Company in 2026
Figure 31. Eosinophilic Disease Revenue by Company in 2026 ($ millions)
Figure 32. Global Eosinophilic Disease Revenue Market Share by Company in 2026
Figure 33. Global Eosinophilic Disease Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Eosinophilic Disease Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 36. Americas Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 37. APAC Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 38. APAC Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 39. Europe Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 40. Europe Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Eosinophilic Disease Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Eosinophilic Disease Revenue 2021-2026 ($ millions)
Figure 43. Americas Eosinophilic Disease Sales Market Share by Country in 2026
Figure 44. Americas Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Figure 45. Americas Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 46. Americas Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 47. United States Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Eosinophilic Disease Sales Market Share by Region in 2026
Figure 52. APAC Eosinophilic Disease Revenue Market Share by Region (2021-2026)
Figure 53. APAC Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 54. APAC Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 55. China Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 59. India Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Eosinophilic Disease Sales Market Share by Country in 2026
Figure 63. Europe Eosinophilic Disease Revenue Market Share by Country (2021-2026)
Figure 64. Europe Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 65. Europe Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 66. Germany Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 67. France Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Eosinophilic Disease Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Eosinophilic Disease Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Eosinophilic Disease Sales Market Share by Application (2021-2026)
Figure 74. Egypt Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Eosinophilic Disease Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Eosinophilic Disease in 2026
Figure 80. Manufacturing Process Analysis of Eosinophilic Disease
Figure 81. Industry Chain Structure of Eosinophilic Disease
Figure 82. Channels of Distribution
Figure 83. Global Eosinophilic Disease Sales Market Forecast by Region (2027-2032)
Figure 84. Global Eosinophilic Disease Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Eosinophilic Disease Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Eosinophilic Disease Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Eosinophilic Disease Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Eosinophilic Disease Revenue Market Share Forecast by Application (2027-2032)
